XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Strategic License and Research and Collaboration Agreements - Additional Information (Details)
£ in Millions
 1 Months Ended 3 Months Ended
Oct. 31, 2023
USD ($)
Feb. 28, 2022
USD ($)
Nov. 30, 2015
USD ($)
Mar. 31, 2024
USD ($)
Mar. 31, 2024
GBP (£)
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Prepaid research and development costs       $ 20,070,000     $ 24,297,000
Research and development expenses       45,757,000   $ 29,485,000  
2015 TSRI License Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Milestones achieved       0      
Milestone Payments $ 300,000            
Accrued Royalties       $ 0      
2015 TSRI License Agreement | Maximum              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Development and regulatory milestone payments     $ 1,500,000        
Commercial milestone payments     $ 3,500,000        
Amgen Research and Collaboration Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Collaboration agreement termination description       The term of the agreement is up to five years, although it will terminate after three years if the Company and Amgen do not mutually agree upon a compensation structure for years four and five. If the parties do not reach an agreement at least 30 days prior to the end of year three, the Amgen Collaboration Agreement will automatically terminate upon its third anniversary. Further, either party can terminate the Amgen Collaboration Agreement upon material uncured breach or bankruptcy by the other party, in which case all amounts that have become due through the date of termination are non-refundable. The term of the agreement is up to five years, although it will terminate after three years if the Company and Amgen do not mutually agree upon a compensation structure for years four and five. If the parties do not reach an agreement at least 30 days prior to the end of year three, the Amgen Collaboration Agreement will automatically terminate upon its third anniversary. Further, either party can terminate the Amgen Collaboration Agreement upon material uncured breach or bankruptcy by the other party, in which case all amounts that have become due through the date of termination are non-refundable.    
Research and collaboration agreement quarterly payments for first two year       $ 50,000,000      
Prepaid research and development costs       9,400,000     $ 6,300,000
Research and development expenses       0   $ 8,100,000  
Amgen Research and Collaboration Agreement | Minimum              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Research and collaboration agreement quarterly payments for third year       $ 12,500,000      
Amgen Research and Collaboration Agreement | Maximum              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Term of the agreement       5 years 5 years    
Vanderbilt Research Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Research and collaboration agreement quarterly payments   $ 1,700,000          
Research agreement expiry date       2023-09 2023-09    
Parkinson's Research Ventures Funding Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Research and development expenses       $ 0      
Funds received upon execution of agreement | £         £ 0.9    
Payments for execution of agreement       $ 1,100,000      
Fund eligible to receive upon completion of certain development milestone | £         1.2    
Maximum repayment amount agreed to pay. | £         8.4    
Parkinson's Research Ventures Funding Agreement | Maximum              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Funds provided for preclinical research and development activities | £         £ 2.1